Creative Planning’s GenMark Diagnostics, Inc GNMK Stock Holding History

Creative Planning’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-200	Closed	-$2K	–	4127
2017 Q2	$2K	Hold	200	–	–	﹤0.01%	4360
2017 Q1	$3K	Hold	200	–	–	﹤0.01%	4215
2016 Q4	$2K	Buy	+200	New	+$2.38K	﹤0.01%	4342
2014 Q2	–	Sell	-300	Closed	-$3K	–	4026
2014 Q1	$3K	Hold	300	–	–	﹤0.01%	3291
2013 Q4	$4K	Buy	+300	New	+$3.64K	﹤0.01%	2942

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Creative Planning's GNMK Position: Q3 2017 in Review

Creative Planning sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2017, closing a stake of 200 shares — an estimated $2K sold.

Creative Planning first reported a position in GNMK in Q4 2013 and held it in 5 quarters. The position peaked at $4K in Q4 2013. 96 funds tracked by Wall St. Rank hold GNMK as of Q3 2017.

Creative Planning reported no remaining GenMark Diagnostics, Inc position as of Q3 2017 after selling out during the quarter.
Creative Planning sold 200 GenMark Diagnostics, Inc shares in Q3 2017, an estimated $2K.
Creative Planning first reported a position in GenMark Diagnostics, Inc in Q4 2013 and held it in 5 quarters.
Creative Planning's GenMark Diagnostics, Inc position peaked at $4K in Q4 2013.
96 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.